|
| 產(chǎn)地 | France |
| 保存條件 | 2-8 ℃ |
| 品牌 | AntibodySystem |
| 貨號(hào) | KDA29104 |
| 用途 | For Research Use Only. |
| 檢測(cè)方法 | Elisa |
| CAS編號(hào) | |
| 保質(zhì)期 | 1 year |
| 適應(yīng)物種 | Lexatumumab |
| 檢測(cè)限 | 0.156 ug /ml |
| 數(shù)量 | 99999 |
| 包裝規(guī)格 | 96 assays |
| 標(biāo)記物 | Unconjugate |
| 純度 | 95%% |
| 樣本 | Plasma, Serum |
| 應(yīng)用 | Elisa |
| 是否進(jìn)口 | 否 |
KDA29104
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Colorimetric
CV<20%
Plasma, Serum
Quantitative
0.156 μg/ml
0.31-5 μg/mL
80-120%
Lexatumumab
HGS-ETR2, CAS: 845816-02-6
Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL). It was developed by Genentech as a drug for the treatment of cancers. This drug has been investigating in various trials for treating cancers including chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. The efficacy and selectivity of drozitumab in rhabdomyosarcoma (RMS) has been evaluated in preclinical models. And results showed that drozitumab is effective, in vitro, against the majority of RMS cell lines that express caspase-8 and, in vivo, may provide long-term control of RMS. In preclinical glioblastoma models, drozitumab has been found to induce apoptosis and colony formation in several glioblastoma cell lines combined with BV6 (combination index<0.1). A study about triple-negative breast cancer reported that drozitumab could induce apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes. The previous study about the treatment of pancreatic ductal adenocarcinoma has revealed that drozitumab could selectively eliminate CSCs, resulting in tumor growth inhibition and even regression of pancreatic tumors.
2-8 ℃
For Research Use Only.
Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.
AntibodySystem由具有30多年蛋白抗體開(kāi)發(fā)經(jīng)驗(yàn)的 創(chuàng)立于法國(guó),專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國(guó)斯特拉斯堡市。AntibodySystem自主開(kāi)發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點(diǎn)蛋白以及對(duì)照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。
普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。
如果您對(duì)我們的產(chǎn)品感興趣,請(qǐng)聯(lián)系027-65279366。
以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)
